NewAmsterdam Pharma reported first quarter 2026 results and a broad clinical update. Revenue was $3.0 million, while net loss widened to $48.4 million from $39.5 million a year earlier. Cash, cash equivalents and marketable securities totaled $707.3 million as of March 31, 2026.
The company highlighted ongoing Phase 3 programs for obicetrapib, including the PREVAIL cardiovascular outcomes trial with over 9,500 patients enrolled, REMBRANDT with 323 patients enrolled, and RUBENS targeting about 300 patients. Interim PREVAIL analysis is planned for 4Q 2026 with results expected in 1Q 2027.
Regulatory decisions in Europe, the UK and Switzerland for obicetrapib and the obicetrapib/ezetimibe fixed‑dose combination are expected in 2H 2026, with potential launches by Menarini in 4Q 2026 in Germany and the UK. The company also described Alzheimer’s biomarker findings from the BROADWAY trial and plans a new trial in early Alzheimer’s disease in 2026.
NewAmsterdam Pharma reported first quarter 2026 results and a broad clinical update. Revenue was $3.0 million, while net loss widened to $48.4 million from $39.5 million a year earlier. Cash, cash equivalents and marketable securities totaled $707.3 million as of March 31, 2026.
The company highlighted ongoing Phase 3 programs for obicetrapib, including the PREVAIL cardiovascular outcomes trial with over 9,500 patients enrolled, REMBRANDT with 323 patients enrolled, and RUBENS targeting about 300 patients. Interim PREVAIL analysis is planned for 4Q 2026 with results expected in 1Q 2027.
Regulatory decisions in Europe, the UK and Switzerland for obicetrapib and the obicetrapib/ezetimibe fixed‑dose combination are expected in 2H 2026, with potential launches by Menarini in 4Q 2026 in Germany and the UK. The company also described Alzheimer’s biomarker findings from the BROADWAY trial and plans a new trial in early Alzheimer’s disease in 2026.
NewAmsterdam Pharma Company N.V. reported first‑quarter 2026 results showing it remains a late‑stage, R&D‑focused biopharma with no approved products and ongoing losses. Revenue was modest at $3.0 million, coming mainly from product supply under the Menarini agreement.
Research and development spending was $38.0 million, down from the prior year as several Phase 3 LDL‑C trials completed, while selling, general and administrative expenses fell to $23.5 million. The company recorded a net loss of $48.4 million, or $0.40 per share.
Cash, cash equivalents and marketable securities totaled $707.3 million, supporting continued investment in the large PREVAIL cardiovascular outcomes trial and other studies of obicetrapib, including work on a fixed‑dose combination with ezetimibe and exploration in Alzheimer’s disease and diabetes‑related indications.
NewAmsterdam Pharma Company N.V. reported first‑quarter 2026 results showing it remains a late‑stage, R&D‑focused biopharma with no approved products and ongoing losses. Revenue was modest at $3.0 million, coming mainly from product supply under the Menarini agreement.
Research and development spending was $38.0 million, down from the prior year as several Phase 3 LDL‑C trials completed, while selling, general and administrative expenses fell to $23.5 million. The company recorded a net loss of $48.4 million, or $0.40 per share.
Cash, cash equivalents and marketable securities totaled $707.3 million, supporting continued investment in the large PREVAIL cardiovascular outcomes trial and other studies of obicetrapib, including work on a fixed‑dose combination with ezetimibe and exploration in Alzheimer’s disease and diabetes‑related indications.
FMR LLC files an amendment to Schedule 13G reporting beneficial ownership of 8,765,811 shares of PHARMA COMPANY NV common stock. The filing states FMR LLC holds 8,765,811 shares, representing 7.6% of the class, with sole dispositive power and no shared voting power reported. The amendment notes related power-of-attorney authority and references Exhibit 99 and an Exhibit 24 power of attorney.
FMR LLC files an amendment to Schedule 13G reporting beneficial ownership of 8,765,811 shares of PHARMA COMPANY NV common stock. The filing states FMR LLC holds 8,765,811 shares, representing 7.6% of the class, with sole dispositive power and no shared voting power reported. The amendment notes related power-of-attorney authority and references Exhibit 99 and an Exhibit 24 power of attorney.
NewAmsterdam Pharma Company N.V. is asking shareholders to vote at its June 2, 2026 annual general meeting in Amsterdam on nine proposals covering financial statements, governance and compensation.
Shareholders are asked to adopt the Dutch statutory annual accounts for 2025, discharge directors from liability for 2025, and instruct and ratify Deloitte Accountants B.V. as external auditor and independent registered public accounting firm for 2026. Two non-executive directors, John W. Smither and Janneke van der Kamp, are up for reappointment with proposed terms running until the 2030 annual meeting.
The agenda also seeks to extend the Board’s authority to issue ordinary shares and to limit or exclude pre-emption rights for up to five years, approve a 2026 Employee Stock Purchase Plan reserving 1,150,000 ordinary shares, and hold a non-binding advisory vote on 2025 compensation for named executive officers. Shareholders of record as of May 5, 2026 may vote in person, by proxy, telephone or internet, subject to the described deadlines and procedures.
NewAmsterdam Pharma Company N.V. is asking shareholders to vote at its June 2, 2026 annual general meeting in Amsterdam on nine proposals covering financial statements, governance and compensation.
Shareholders are asked to adopt the Dutch statutory annual accounts for 2025, discharge directors from liability for 2025, and instruct and ratify Deloitte Accountants B.V. as external auditor and independent registered public accounting firm for 2026. Two non-executive directors, John W. Smither and Janneke van der Kamp, are up for reappointment with proposed terms running until the 2030 annual meeting.
The agenda also seeks to extend the Board’s authority to issue ordinary shares and to limit or exclude pre-emption rights for up to five years, approve a 2026 Employee Stock Purchase Plan reserving 1,150,000 ordinary shares, and hold a non-binding advisory vote on 2025 compensation for named executive officers. Shareholders of record as of May 5, 2026 may vote in person, by proxy, telephone or internet, subject to the described deadlines and procedures.
NewAmsterdam Pharma Company N.V. reports that Chief Accounting Officer Louise Kooij will end her employment effective August 31, 2026. The company and Ms. Kooij entered into a separation agreement on April 24, 2026.
Under this agreement, she is eligible for a lump-sum payment equal to twelve months of her current base salary, a pro-rated 2026 annual cash bonus based on target achievement through the separation date, and payment for accrued but unused holiday and vacation days in line with Dutch law.
The company will extend vesting of her outstanding stock options and RSU awards through January 10, 2027, and vested stock options will remain exercisable until February 10, 2027. The agreement also includes confidentiality, non-compete and non-disparagement covenants and a release of claims, and is expected to be filed with the company’s Form 10-Q for the quarter ending June 30, 2026.
NewAmsterdam Pharma Company N.V. reports that Chief Accounting Officer Louise Kooij will end her employment effective August 31, 2026. The company and Ms. Kooij entered into a separation agreement on April 24, 2026.
Under this agreement, she is eligible for a lump-sum payment equal to twelve months of her current base salary, a pro-rated 2026 annual cash bonus based on target achievement through the separation date, and payment for accrued but unused holiday and vacation days in line with Dutch law.
The company will extend vesting of her outstanding stock options and RSU awards through January 10, 2027, and vested stock options will remain exercisable until February 10, 2027. The agreement also includes confidentiality, non-compete and non-disparagement covenants and a release of claims, and is expected to be filed with the company’s Form 10-Q for the quarter ending June 30, 2026.
NewAmsterdam Pharma Co N.V. Chief Scientific Officer Johannes Jacob Pieter Kastelein, through Futurum B.V., exercised options for 300,000 Ordinary Shares at an exercise price of EUR 1.16392 and sold 300,000 shares in open-market transactions around $30 per share between March 5–9, 2026. The shares and options are held indirectly via Futurum and NAP PoolCo B.V. for his benefit, with the reporting person retaining sole voting and investment control.
NewAmsterdam Pharma Co N.V. Chief Scientific Officer Johannes Jacob Pieter Kastelein, through Futurum B.V., exercised options for 300,000 Ordinary Shares at an exercise price of EUR 1.16392 and sold 300,000 shares in open-market transactions around $30 per share between March 5–9, 2026. The shares and options are held indirectly via Futurum and NAP PoolCo B.V. for his benefit, with the reporting person retaining sole voting and investment control.
NAMS submitted a Form 144 reporting proposed sales of Ordinary Shares through J.P. Morgan Securities LLC. The filing lists multiple lots acquired via RSU awards, purchases and option exercise on dates including 12/11/2025, 05/13/2025, 04/02/2025, 02/14/2024, 12/19/2023, and 06/07/2023, with lot sizes shown such as 68, 69, 3,102, 5,000, 9,787, and 10,000. The broker is listed as J.P. Morgan Securities LLC on Nasdaq.
NAMS submitted a Form 144 reporting proposed sales of Ordinary Shares through J.P. Morgan Securities LLC. The filing lists multiple lots acquired via RSU awards, purchases and option exercise on dates including 12/11/2025, 05/13/2025, 04/02/2025, 02/14/2024, 12/19/2023, and 06/07/2023, with lot sizes shown such as 68, 69, 3,102, 5,000, 9,787, and 10,000. The broker is listed as J.P. Morgan Securities LLC on Nasdaq.
NewAmsterdam Pharma Co N.V. CEO Michael H. Davidson reported an option exercise-and-sell transaction on March 2, 2026. He exercised options for 443,707 ordinary shares at EUR 1.16392 per share and sold 443,707 shares at $33.25 per share.
Following the transactions, Davidson held 174,144 ordinary shares directly, with 239,267 options remaining under the reported grant.
NewAmsterdam Pharma Co N.V. CEO Michael H. Davidson reported an option exercise-and-sell transaction on March 2, 2026. He exercised options for 443,707 ordinary shares at EUR 1.16392 per share and sold 443,707 shares at $33.25 per share.
Following the transactions, Davidson held 174,144 ordinary shares directly, with 239,267 options remaining under the reported grant.
NewAmsterdam Pharma submitted a Form 144 notice reporting the proposed sale of 443,707 ordinary shares by option exercise on 03/02/2026 for cash on Nasdaq. The filing also lists recent sales by Michael Davidson totaling 318,145 shares across 01/07/2026–02/26/2026.
NewAmsterdam Pharma submitted a Form 144 notice reporting the proposed sale of 443,707 ordinary shares by option exercise on 03/02/2026 for cash on Nasdaq. The filing also lists recent sales by Michael Davidson totaling 318,145 shares across 01/07/2026–02/26/2026.